# Neurofenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurofenix

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.neurofenix.com
- Total disclosed funding: $9.6M
- Latest round: Series A (Jul 20, 2022)
- Investors on record: 4

## About

Neurofenix Ltd. is a healthcare technology company focused on virtual neurorehabilitation solutions that enhance recovery for patients with neurological conditions through innovative, gamified therapy methods.Founded in 2016 and headquartered in London, UK, Neurofenix Ltd. specializes in delivering virtual neurorehabilitation services. The company has secured a total of three deals, with the latest funding round occurring on July 20, 2022. This round was a Series A funding of GBP 6.33 million led by Albion Capital, which also included Health Technology Holding and InHealth Ventures as investors. The company's founders, Dimitris Athanasiou and Guillem Buxarrais, have a background in healthcare technology and innovation.Neurofenix specializes in virtual neurorehabilitation solutions aimed at enhancing the recovery and rehabilitation of patients with neurological conditions. The company’s primary offerings include a tech-enabled platform that delivers personalized, gamified therapy sessions designed to improve neuroplasticity and functional outcomes. Their flagship product, the NeuroBall, facilitates high-repetition, high-intensity therapy tailored to individual patient needs. This service model caters to patients directly and supports healthcare providers looking to extend their neuro rehab offerings seamlessly into patients' homes, ensuring nationwide accessibility across the United States.Neurofenix generates revenue through a subscription-based model, allowing patients and healthcare providers to enroll in their virtual care programs. Clients engage with the company for ongoing therapy sessions, monitored via the NeuroPlatform and Dashboard for real-time tracking of patient progress. The pricing structure accommodates a range of clients, promoting tailored care plans that support direct-to-consumer sales and partnerships with healthcare providers and facilities integrating comprehensive neuro rehab services.In July 2022, Neurofenix Ltd. raised GBP 6.33 million in Series A funding, which will be utilized for expanding into the U.S. market, supporting clinical trials, and growing their teams. The company is focused on launching additional innovative products and enhancing its existing offerings to improve patient care. Neurofenix aims to establish a robust presence in new geographic regions, specifically targeting the U.S. healthcare landscape by leveraging its recent funding.

## Funding rounds

- Series A, Jul 20, 2022, $7.6M — Albion Capital, InHealth Ventures, Health Technology Holding
- Seed, Jan 15, 2020, $1.9M — O2h Ventures

## Investors

- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Seed
- Albion Capital — Series A
- InHealth Ventures (https://capitalatlas.ai/funds/inhealth-ventures) — Series A
- Health Technology Holding (https://capitalatlas.ai/funds/health-technology-holding) — Series A